Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million ...

Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon, a bookrunner said on ...

Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health ...

Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines.

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...

The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.

Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital. The pharmaceutical giant said ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...